ZELBORAF Film-coated Tablet
Vemurafenib
240 mg
APOGEPHA ARZNEIMITTEL GmbH
| Pack size | 56's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 1.29 AED |
Indications
ZELBORAF Film-coated Tablet is used for:
Treatment of unresectable or metastatic melanoma in patients with the BRAF-V600 mutation.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Vemurafenib :
Mechanism of Action
Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase. It is especially potent against the BRAF V600E mutation. This mutation involves the substitution of glutamic acid for valine at codon 600. The BRAF oncogene, most of which have the V600E mutation, activates mitogen-activated kinase (MAPK) pathway which results in cell growth, proliferation, and metastasis. Vemurafenib blocks these downstream processes to inhibit tumour growth and eventually trigger apoptosis. Vemurafenib does not have antitumour effects against melanoma cell lines with the wild-type BRAF mutation.
Note
ZELBORAF 240 mg Film-coated Tablet manufactured by APOGEPHA ARZNEIMITTEL GmbH. Its generic name is Vemurafenib. ZELBORAF is availble in Saudi Arabia.
Farmaco SA drug index information on ZELBORAF Film-coated Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.